| MeSH term | MeSH ID | Detail |
|---|---|---|
| Prosthesis-Related Infections | D016459 | 7 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Tooth Discoloration | D014075 | 7 associated lipids |
| Sinusitis | D012852 | 9 associated lipids |
| Fusobacterium Infections | D005674 | 3 associated lipids |
| Enterocolitis, Pseudomembranous | D004761 | 8 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
| Urinary Tract Infections | D014552 | 11 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Pseudomonas Infections | D011552 | 25 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Rezvanian E and Watson NF | Kleine-levin syndrome treated with clarithromycin. | 2013 | J Clin Sleep Med | pmid:24235906 |
| Cosme A et al. | Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. | 2013 | Clin. Microbiol. Infect. | pmid:22512623 |
| Srivastava S et al. | Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? | 2013 | Eur. Respir. J. | pmid:24293417 |
| Gui J et al. | [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing]. | 2013 | Zhonghua Jie He He Hu Xi Za Zhi | pmid:24252731 |
| AvÅŸar E et al. | A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients. | 2013 | Turk J Gastroenterol | pmid:24254262 |
| Smiley R et al. | Comparative proteomics analysis of sarcosine insoluble outer membrane proteins from clarithromycin resistant and sensitive strains of Helicobacter pylori. | 2013 | J. Microbiol. | pmid:24173641 |
| Lally L and Mannion L | The potential for antimicrobials to adversely affect mental state. | 2013 | BMJ Case Rep | pmid:23833088 |
| Berghaus LJ et al. | Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. | 2013 | Vet. Microbiol. | pmid:23915992 |
| [Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial]. | 2013 | Jpn J Antibiot | pmid:24930240 | |
| Khamraev AA et al. | [State of mucosal barrier of the stomach after Helicobacter pylori eradication and ulcer healing in patients with duodenal ulcer disease]. | 2013 | Eksp Klin Gastroenterol | pmid:24933985 |
| Avci O et al. | A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. | 2013 | J Dermatolog Treat | pmid:21923567 |
| Pasipanodya JG and Gumbo T | Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions. | 2013 | Am. J. Respir. Crit. Care Med. | pmid:23457368 |
| Sasaki H et al. | Ten-year trend of the cumulative Helicobacter pylori eradication rate for the 'Japanese eradication strategy'. | 2013 | Digestion | pmid:24356705 |
| Yakoob J et al. | Low rate of recurrence of Helicobacter pylori infection in spite of high clarithromycin resistance in Pakistan. | 2013 | BMC Gastroenterol | pmid:23433429 |
| Yuan Y et al. | Optimum duration of regimens for Helicobacter pylori eradication. | 2013 | Cochrane Database Syst Rev | pmid:24338763 |
| Amin M et al. | Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. | 2013 | Molecules | pmid:23434867 |
| Ogata SK et al. | High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. | 2013 | J. Pediatr. Gastroenterol. Nutr. | pmid:23403439 |
| Morgan DR et al. | Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. | 2013 | JAMA | pmid:23403682 |
| Naserpour Farivar T et al. | Prevalence of clarithromycin-resistant Helicobacter pylori in patients with chronic tonsillitis by allele-specific Scorpion real-time polymerase chain reaction assay. | 2013 | Laryngoscope | pmid:23404672 |
| Koh WJ et al. | Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. | 2013 | Antimicrob. Agents Chemother. | pmid:23478956 |
| Lee G et al. | Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. | 2013 | Ann Am Thorac Soc | pmid:23952847 |
| Kate V et al. | Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. | 2013 | Drugs | pmid:23625272 |
| Kato H et al. | Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide. | 2013 | Ann. Hematol. | pmid:23625297 |
| Bolhuis MS et al. | Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. | 2013 | Antimicrob. Agents Chemother. | pmid:23689722 |
| Seddik H et al. | Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. | 2013 | Eur. J. Clin. Pharmacol. | pmid:23695545 |
| Ohe M and Hashino S | Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide. | 2013 | Korean J. Intern. Med. | pmid:23682236 |
| Sadeghifard N et al. | Survey in Iran of clarithromycin resistance in Helicobacter pylori isolates by PCR-RFLP. | 2013 | Southeast Asian J. Trop. Med. Public Health | pmid:23682442 |
| Serelis J et al. | Granulomatous infection of the hand and wrist due to Azospirillum spp. | 2013 | Diagn. Microbiol. Infect. Dis. | pmid:23685031 |
| Togami K et al. | Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro. | 2013 | Biol. Pharm. Bull. | pmid:23995662 |
| Kute VB et al. | Bronchiolitis obliterans organizing pneumonia (BOOP) after renal transplantation. | 2013 | Int Urol Nephrol | pmid:22547135 |
| Vu DH et al. | Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. | 2013 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:23353809 |
| Kim SG et al. | Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial. | 2013 | Dig Liver Dis | pmid:23333104 |
| Lim JH et al. | Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. | 2013 | Helicobacter | pmid:23305083 |
| James GD et al. | Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. | 2013 | Prim Care Respir J | pmid:23839240 |
| Dumpis U et al. | Assessment of antibiotic prescribing in Latvian general practitioners. | 2013 | BMC Fam Pract | pmid:23311389 |
| Huang CW et al. | Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. | 2013 | Int. J. Antimicrob. Agents | pmid:23312605 |
| Liu X et al. | Clarithromycin-loaded liposomes offering high drug loading and less irritation. | 2013 | Int J Pharm | pmid:23337631 |
| Chodkiewicz HM and Cohen PR | Erythrasma: successful treatment after single-dose clarithromycin. | 2013 | Int. J. Dermatol. | pmid:23046434 |
| Jouneau S et al. | Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. | 2013 | Respiration | pmid:23095475 |
| Higashida A et al. | Effectiveness of esomeprazole-based triple therapy of H. pylori in young patients in Japan. | 2013 | Scand. J. Gastroenterol. | pmid:23016956 |
| Kim MS et al. | Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. | 2013 | Helicobacter | pmid:23066652 |
| Xiong LJ et al. | Detection of clarithromycin-resistant Helicobacter pylori by stool PCR in children: a comprehensive review of literature. | 2013 | Helicobacter | pmid:23067446 |
| Tsuji D et al. | Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. | 2013 | Chemotherapy | pmid:25011542 |
| Pilcer G et al. | New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. | 2013 | J Pharm Sci | pmid:23568616 |
| Feng Z et al. | Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis. | 2013 | J. Int. Med. Res. | pmid:23569151 |
| Gokmen T et al. | Clarithromycin treatment in preterm infants: a pilot study for prevention of feeding intolerance. | 2013 | J. Matern. Fetal. Neonatal. Med. | pmid:23570248 |
| Semino-Mora C et al. | Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution. | 2013 | Clin. Cancer Res. | pmid:23743566 |
| Zullo A et al. | Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. | 2013 | Clin Res Hepatol Gastroenterol | pmid:23747131 |
| Markert C et al. | Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. | 2013 | Eur. J. Clin. Pharmacol. | pmid:23748747 |
| Nishizawa T et al. | Delay of second-line eradication therapy for Helicobacter pylori can increase eradication failure. | 2013 | J. Gastroenterol. Hepatol. | pmid:23701705 |